Zoetis Inc. logo
Zoetis Inc. (ZTS)
Compare

ZTS Income Statement

Revenue, expenses, and profitability analysis

ZTS Quarterly Income Statement (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
6.728B1.621B1.644B1.685B1.778B1.566B1.576B1.652B1.658B
9.509B2.262B2.387B2.400B2.460B2.220B2.317B2.388B2.361B
Cost of Goods Sold
2.781B641.000M743.000M715.000M682.000M654.000M741.000M736.000M703.000M
71.7%71.7%68.9%70.2%72.3%70.5%68.0%69.2%70.2%
Total Operating Expenses
3.155B799.000M818.000M749.000M789.000M720.000M811.000M732.000M752.000M
721.000M180.000M199.000M170.000M172.000M157.000M186.000M167.000M171.000M
2.403B588.000M619.000M579.000M617.000M563.000M625.000M565.000M581.000M
3.573B822.000M826.000M936.000M989.000M846.000M765.000M920.000M906.000M
36.3%36.3%34.6%39.0%40.2%38.1%33.0%38.5%38.4%
3.308B758.000M761.000M887.000M902.000M810.000M732.000M874.000M780.000M
Interest Income
91.000M21.000M25.000M26.000M19.000M23.000M27.000M23.000M24.000M
241.000M62.000M57.000M64.000M58.000M59.000M56.000M61.000M63.000M
Other Income/Expense
-265.000M-64.000M-65.000M-49.000M-87.000M-36.000M-33.000M-46.000M-126.000M
2.643B601.000M603.000M721.000M718.000M631.000M581.000M682.000M624.000M
665.000M157.000M158.000M166.000M184.000M179.000M151.000M182.000M156.000M
26.6%26.6%25.3%30.0%29.2%28.4%25.1%28.6%26.4%
4.040B941.000M947.000M1.069B1.083B988.000M911.000M1.056B970.000M
EBITDA Margin
41.6%41.6%39.7%44.5%44.0%44.5%39.3%44.2%41.1%
487.000M119.000M121.000M124.000M123.000M119.000M123.000M121.000M127.000M
EPS Basic
6.041.421.381.631.611.411.291.511.37
6.031.421.371.631.611.411.291.501.37
Shares Outstanding
422.100M422.100M438.200M442.900M445.100M447.600M450.500M452.900M455.500M
Diluted Shares Outstanding
422.400M422.400M438.600M443.200M445.500M448.000M451.100M453.500M456.000M

ZTS Annual Income Statement (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
6.673B6.396B5.834B5.476B5.312B4.458B4.113B3.797B
9.467B9.256B8.544B8.080B7.776B6.675B6.260B5.825B
Cost of Goods Sold
2.794B2.860B2.710B2.604B2.464B2.217B2.147B2.028B
70.5%69.1%68.3%67.8%68.3%66.8%65.7%65.2%
Total Operating Expenses
3.076B3.004B2.765B2.548B2.509B2.189B2.095B1.916B
698.000M686.000M614.000M539.000M508.000M463.000M457.000M432.000M
2.378B2.318B2.151B2.009B2.001B1.726B1.638B1.482B
3.597B3.392B3.069B2.928B2.803B2.269B2.018B1.881B
38.0%36.6%35.9%36.2%36.0%34.0%32.2%32.3%
3.360B3.133B2.936B2.656B2.488B1.996B1.801B1.690B
Interest Income
93.000M106.000M105.000M50.000M6.000M12.000M37.000M31.000M
243.000M242.000M258.000M237.000M236.000M249.000M242.000M212.000M
Other Income/Expense
-237.000M-259.000M-133.000M-272.000M-315.000M-273.000M-217.000M-191.000M
2.673B2.486B2.344B2.114B2.037B1.638B1.500B1.428B
687.000M637.000M596.000M545.000M454.000M360.000M301.000M266.000M
28.2%26.9%27.4%26.2%26.2%24.5%24.0%24.5%
4.069B3.872B3.685B3.358B3.172B2.686B2.455B2.210B
EBITDA Margin
43.0%41.8%43.1%41.6%40.8%40.2%39.2%37.9%
487.000M497.000M491.000M465.000M448.000M441.000M412.000M308.000M
EPS Basic
6.035.475.084.514.293.443.142.96
6.025.475.074.494.273.423.112.93
Shares Outstanding
443.443M454.200M461.172M468.891M474.348M475.502M478.128M483.063M
Diluted Shares Outstanding
443.835M454.848M462.269M470.385M476.717M478.569M481.787M486.898M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Parsippany, NJ
13,800 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Kristin C. Peck